$LBRX News

2 Reasons LB Pharmaceuticals (LBRX) Looks Pricey Following Its CFO Appointment

LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer

LB Pharmaceuticals Appoints Joseph Miller CFO

HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60

BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54

LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate

HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target

LB Pharmaceuticals Announces $150 Million Private Placement

LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded Warrants

LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophrenia

LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027

BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46

LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

Wolfe Research Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $45

LB Pharmaceuticals Inc. (LBRX) Maintains Buy Rating as Analyst Highlights LB-102 Potential

LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations

LB Pharmaceuticals to Participate in Upcoming June Investor Events

All You Need to Know About LB Pharmaceuticals Inc (LBRX) Rating Upgrade to Buy

LB Pharmaceuticals (NASDAQ:LBRX) Is In A Good Position To Deliver On Growth Plans